» Articles » PMID: 25490065

Inhibition of Plasmin Protects Against Colitis in Mice by Suppressing Matrix Metalloproteinase 9-mediated Cytokine Release from Myeloid Cells

Abstract

Background & Aims: Activated proteases such as plasmin and matrix metalloproteinases (MMPs) are activated in intestinal tissues of patients with active inflammatory bowel diseases. We investigated the effect of plasmin on the progression of acute colitis.

Methods: Colitis was induced in Mmp9(-/-), Plg(-/-), and C57BL/6 (control) mice by the administration of dextran sulfate sodium, trinitrobenzene sulfonic acid, or CD40 antibody. Plasmin was inhibited in control mice by intraperitoneal injection of YO-2, which blocks its active site. Mucosal and blood samples were collected and analyzed by reverse-transcription polymerase chain reaction and immunohistochemical analyses, as well as for mucosal inflammation and levels of cytokines and chemokines.

Results: Circulating levels of plasmin were increased in mice with colitis, compared with controls. Colitis did not develop in control mice injected with YO-2 or in Plg(-/-) mice. Colons from these mice had reduced infiltration of Gr1+ neutrophils and F4/80+ macrophages, and reduced levels of inflammatory cytokines and chemokines. Colonic inflammation and colitis induction required activation of endogenous MMP9. After colitis induction, mice given YO-2, Plg(-/-) mice, and Mmp9(-/-) mice had reduced serum levels of tumor necrosis factor and C-X-C motif chemokine ligand 5, compared with control mice.

Conclusions: In mice, plasmin induces a feedback mechanism in which activation of the fibrinolytic system promotes the development of colitis via activation of MMP9 or proteolytic enzymes. The proteolytic environment stimulates the influx of myeloid cells into the colonic epithelium and the production of tumor necrosis factor and C-X-C motif chemokine ligand 5. In turn, myeloid CD11b+ cells release the urokinase plasminogen activator, which accelerates plasmin production. Disruption of the plasmin-induced chronic inflammatory circuit therefore might be a strategy for colitis treatment.

Citing Articles

Common diagnostic biomarkers and molecular mechanisms of infection and inflammatory bowel disease.

Zhang M, Liu T, Luo L, Zhang Y, Chen Q, Wang F Front Immunol. 2024; 15:1492810.

PMID: 39712025 PMC: 11659760. DOI: 10.3389/fimmu.2024.1492810.


The influence of 4G/5G polymorphism in the plasminogen-activator-inhibitor-1 promoter on COVID-19 severity and endothelial dysfunction.

Yatsenko T, Rios R, Nogueira T, Salama Y, Takahashi S, Adachi E Front Immunol. 2024; 15:1445294.

PMID: 39281671 PMC: 11392769. DOI: 10.3389/fimmu.2024.1445294.


Enhancing the revelation of key genes and interaction networks in non-small cell lung cancer with major depressive disorder: A bioinformatics analysis.

Gui H, Chen X, Nie Y, Zhang X Health Sci Rep. 2024; 7(6):e2167.

PMID: 38933422 PMC: 11199184. DOI: 10.1002/hsr2.2167.


Lactate Protects Intestinal Epithelial Barrier Function from Dextran Sulfate Sodium-Induced Damage by GPR81 Signaling.

Li X, Yao Z, Qian J, Li H, Li H Nutrients. 2024; 16(5).

PMID: 38474712 PMC: 10934655. DOI: 10.3390/nu16050582.


Urokinase-type plasminogen activator blockade ameliorates experimental colitis in mice.

Kida Y, Okahisa T, Sato Y, Bando M, Fujimoto S, Ma B Sci Rep. 2023; 13(1):2899.

PMID: 36806262 PMC: 9938860. DOI: 10.1038/s41598-023-29824-1.